Company intelligence / Profile preview

Neurognos

Ownership: Private
Development stage: Other

Overview

Neurognos develops non-invasive diagnostic solutions for early detection of Alzheimer's and other neurodegenerative diseases using blood-based microRNA signatures analyzed by proprietary machine learning algorithms. The company aims to enable accessible, early intervention before symptoms arise. Specific clinical results are not publicly detailed, but the technology leverages validated biomarker discovery and computational analytics.

Therapeutic areas: Neurology
Modalities: Diagnostic test (miRNA-based)Machine learning algorithm (for biomarker analysis)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Neurognos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurognos.

Explore the full profile